CClinicalTrials.gg
CompletedNCT03423719Updated Feb 6, 2018

Evaluation of Fiit-ns® in Health-related Quality of Life Improvement in Overweight and Obese Subjects

An interventional study of Fiit-ns® and Placebo in Overweight and Obesity, sponsored by Fytexia. Completed at 1 site in Spain. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-06.

Sponsored by Fytexia · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effects of a 16-week supplementation with a polyphenol-rich extract, Fiit-ns®, on improvement of health-related quality of life (HR-QOL) of overweight and obese volunteers, as compared to placebo. Previous beneficial results from a pilot study showed that the supplementation may improve quality of life as well as body composition. Based on such results, this pivotal study is statistically powered to detect significant differences in HR-QOL assessed with the Short Form-36 Health survey (SF-36) between baseline (Week 1, W1) and end of the supplementation period (Week 16, W16).

02

Conditions studied

  • Overweight and Obesity

Browse trials for

03

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 25 kg/m2 ≤ Body Mass Index (BMI) ≤ 40 kg/m2
  • 25-55 years old

Exclusion criteria

Exclusion Criteria:

  • Metabolic and/or chronic disease (diabetes, dyslipidemia, thyroiditis, inflammatory disease, immunological disease, asthma, anxiety, depression)
  • Allergy to one of the ingredients of the supplement
  • Current involvement of involvement within the 6 previous months in a chronic supplement program, chronic treatment program, weight loss program
  • Smoking cessation
  • High alcohol consumption
  • Pregnancy
  • Breastfeeding
  • Menopausal women
  • Involvement in physical activity more than twice a week
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Verum

    This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.

    Dietary Supplement: Fiit-ns®

  • Placebo comparator
    Placebo

    This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementFiit-ns®

    Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.

  • Dietary supplementPlacebo

    Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.

05

What researchers measure

Primary outcomes

  1. Change in health-related quality of life as assessed by the SF-36 Health Survey

    Time frame: Baseline (Week 1) and end of the supplementation period (Week 16)

Secondary outcomes

  1. Change in body weight

    Change in body weight is measured with calibrated weighing scales

    Time frame: Baseline (Week 1) and end of the supplementation period (Week 16)

  2. Change in waist circumference

    Change is waist circumference is measured with a non-stretchable tape and used to calculate change in Index of Central Obesity (ICO)

    Time frame: Baseline (Week 1) and end of the supplementation period (Week 16)

  3. Change in total body fat mass

    Change in total body fat mass is measured with Dual-Energy X-ray Absorptiometry (DXA) scan

    Time frame: Baseline (Week 1) and end of the supplementation period (Week 16)

  4. Change in trunk fat mass

    Change in trunk fat mass is measured with Dual-Energy X-ray Absorptiometry (DXA) scan

    Time frame: Baseline (Week 1) and end of the supplementation period (Week 16 )

  5. Change in physical activity level

    Physical activity is assessed with International Physical Activity Questionnaire (IPAQ) IPAQ consists in 27 items that cover 4 different domains of physical activity (working, transportation, housework and gardening \& leisure-time) in terms of time spent during the 7 previous days. Total score is the sum of the 4 domains and results are presented as an estimation of energy expenditure in metabolic equivalent-minutes per week (Met-min/week).

    Time frame: Baseline (Week 1) and end of the supplementation period (Week 16)

06

Study locations

1 site
  • UCAM (Universidad Catolica San Antonio de Murcia)
    Murcia, Spain
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03423719
Lead sponsor
Fytexia
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Apr 2015
Primary completion
Sep 2016
Completion
Sep 2017
Last update
Feb 6, 2018

Study contacts

Pedro E Alcaraz Ramon
principal investigator · UCAM (Universidad Catolica San Antonio de Murcia)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion